Monthly Intramuscular Neridronate for the Treatment of Postmenopausal Osteoporosis: Results of a 6-Year Prospective Italian Study
Table 1
Patient characteristics and DEXA parameters at baseline.
Characteristics
Overall population ()
Age at study entry (years)
(49.5-80.4)
Age at menopause (years)
(35.0-55.0)
Smoking status
Never
51 (85)
Former
8 (13.3)
Current
1 (1.7)
BMI (kg/m2)
(18.8-31.9)
SBP (mmHg)
(100-172)
DBP (mmHg)
(55-88)
HR
(50-89)
Comorbidities
Dyslipidemia
52 (86.7)
Hypercolesterolemia
48 (80)
Hypertension
42 (70)
Hypothyroidism
30 (50)
Hypo-vitB12 or folate
6 (10)
DM2
2 (3.3)
DEXA parameter
-score L1-L4
(−4.2-0.8)
-score FN
(−3.3-0.6)
-score TF
(−3.4-0.7)
BMD (g/cm2) L1-L4
(0.542-0.935)
BMD (g/cm2) FN
(0.485-0.739)
BMD (g/cm2) TF
(0.530-0.923)
Data are expressed as deviation (SD) and range (min-max), or frequencies ( [%]). Abbreviations: BMI: body mass index; SBP: systolic blood pressure; DBP: diastolic blood pressure; HR: heart rate; vitB12: vitamin B12; DM2: diabetes mellitus type 2; L1-L4: lumbar spine; FN: femoral neck; TF: total femur; BMD: bone mineral density.